deltatrials
Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05216562

Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients (EXOMSC-COV19)

Efficacy and Safety of EXOSOME-MSC (Mesenchymal Stem Cell-Derived Exosomes) Therapy to Reduce Hyper-inflammation In Moderate COVID-19 (2019- New Corona Virus Disease) Patients

Sponsor: Dermama Bioteknologi Laboratorium

Conditions SARS-CoV2 Infection
Interventions COVID-19 Standard Treatment Exosome-MSC Intravenous injection Placebo Intravenous Injection
Updated 5 times since 2022 Last updated: Feb 3, 2022 Started: Jul 1, 2021 Primary completion: Jun 30, 2022 Completion: Dec 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates SARS-CoV2 Infection and is currently ongoing. Dermama Bioteknologi Laboratorium leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshotRecruiting~Mar 2022 – ~Mar 2024 · 24 months · monthly snapshotRecruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2/PHASE3

    Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Mar 2024 — Jul 2024 [monthly]

    Unknown Status PHASE2_PHASE3

    Status: Recruiting → Unknown Status

  4. Mar 2022 — Mar 2024 [monthly]

    Recruiting PHASE2_PHASE3

  5. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dermama Bioteknologi Laboratorium
  • Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
Data source: Dermama Bioteknologi Laboratorium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations